Document:

MEGA
BRIDGE INC TO
BE KNOWN AS

 

HYPGEN
INC.

 

CONSULTING
AGREEMENT

 

 

THIS
AGREEMENT, dated this 8th day of JULY 2017, is made by and between MEGA BRIDGE INC., a
Nevada Corporation with primary place of business at 501
Madison Avenue 14th Floor. New York, NY 10022 and its successors (the “Company”), and
Richard L. Chang Holdings, LLC with primary address at 5511 Paseo Del Lago West, Laguna Woods, CA 92637 (the “CONSULTANT”).

 

In
consideration of the mutual covenants herein contained and of the mutual benefits herein provided, the Company and the CONSULTANT
agree as follows:

 

		1.	Representations
                                         and Warranties.

 

The
CONSULTANT represents and warrants to the Company that the CONSULTANT is not bound by any restrictive covenants and has no prior
or other obligations or commitments of any kind that would in any way prevent, restrict, hinder or interfere with the CONSULTANT’s
acceptance of continued engagement or the performance of all duties and services to the fullest extent of the CONSULTANT’s
ability and knowledge.

 

		2.	Term
                                         of Consultancy.

 

The
Company will engage the CONSULTANT for a term commencing on July 8, 2017 and continuing until the date which is 2 years after
the date.

 

		3.	Duties
                                         and Functions.

 

The
Consultant agrees to provide the following services:

 

		•	Assist
                                         the Company with Clinical operations;

		•	Assist
                                         the Company in managing their patents/Intellectual Property;

		•	Assist
                                         the company in technical matters in manufacturing the drug, R&D and science.

 

The
CONSULTANT shall report directly to the Company’s CEO and /or Board of Directors (the “Board”). The CONSULTANT
agrees to perform such modified, different or additional duties as may, from time
to time, be assigned by the Board. At the CONSULTANT’s discretion, the CONSULTANT may perform his duties under this Agreement
at an office provided by the Company or elsewhere.

 

		4.	Compensation.

 

(a) Fees:
As compensation for his services, the
Company agrees to pay the CONSULTANT a base fee of $89.28/hour for 28 hours of work per
month payable on a monthly basis ($2500 per month), initial first payment on the 15th day
of every month starting July 15th, 2017. In the event the Company is unable to pay the
CONSULTANT monthly, the fees shall accrue without interest. This rate may be adjusted if

agreed
upon by the CEO and /or Board.

    	 	1	 

    	 	 	 

    

(b)
Equity: Intentionally left blank

 

(c)
Other Expenses: In addition to the compensation provided for above, the Company agrees to pay or to reimburse the
CONSULTANT during his engagement for all travel, reasonable, ordinary and necessary, properly documented and client-related business
or entertainment expenses incurred in the performance of his services hereunder in accordance with Company policy in effect, on
a monthly basis; provided that all such expenses are pre-approved in writing by the Company’s CEO. The CONSULTANT shall
submit invoices and receipts on a monthly basis for all expenses for which reimbursement is sought. The CONSULTANT shall be granted
business class tickets for all flights to Europe, Asia or flights of over 5 hours flight time.

 

		5.	Indemnification,
                                         Legal Expenses.

 

The
Company and CONSULTANT understand that the CONSULTANT and any and all costs, including legal fees, incurred by the CONSULTANT
in his capacity as legally performing his duties as a consultant will be indemnified and reimbursed by the Company.

 

		6.	Termination.

 

(a) 
Voluntary Termination By
CONSULTANT. Notwithstanding the foregoing, the CONSULTANT may terminate the relationship at any time for any reason
by giving the Company at least sixty (60) days’ written notice. The Company, at its election, may (i) require the CONSULTANT
to continue to perform his duties hereunder for the full notice period, or (ii) terminate the CONSULTANT at any time during such
notice period, provided that any such termination shall not be deemed to be a Termination Without Cause of the CONSULTANT
by the Company.

 

 

(b) 
Termination By
Company For Cause. Notwithstanding the foregoing, the Company may terminate the CONSULTANT under this Agreement
for cause at any time during the Agreement Term, upon providing the CONSULTANT with written notice of the Termination For Cause.
If the CONSULTANT is terminated for cause, the CONSULTANT will not be entitled to and shall not receive any compensation or benefits
of any type following the effective date of termination, although all compensation accrued prior thereto shall remain the CONSULTANT’s
(including the shares granted in this Agreement). As used in this Agreement, the term “Cause” shall include, without
limitation: dishonesty; fraud; serious dereliction of duty; criminal activity; acts of moral turpitude; conviction of a felony,
plea of guilty or nolo contendere to a felony charge or any criminal act involving moral turpitude.

 

(c) 
Termination By
Company Without Cause. Upon thirty (60) days’ written notice, the Company may terminate the CONSULTANT without
cause. If the CONSULTANT’s engagement is terminated by the Company without cause at any time after the $1M Financing Date,
the CONSULTANT shall continue to receive his base fee and any bonus payments for a period of six (6) months from the effective
date of termination (the “Severance Period”).

 

The
compensation to be paid or provided under this Section 5(c) are referred to herein as the “Termination
Compensation.” The CONSULTANT shall not be entitled to any Termination Compensation unless: (i) the CONSULTANT complies
with all surviving provisions of any non- competition agreement, non-solicitation agreement, confidentiality agreement or
inventions assignment agreement that he signed, and (ii) the CONSULTANT executes and delivers to the Company after a notice
of termination a release in form and substance acceptable to the Company, by which the CONSULTANT releases the Company from
any obligations and liabilities of any type whatsoever under this Agreement, except for the Company’s obligations with
respect to the Termination Compensation, and that release shall not affect the CONSULTANT’s right to indemnification,
if any, for actions taken within the scope of his engagement. Notwithstanding anything herein, no Termination Compensation
shall be paid or otherwise provided until all applicable revocation periods have fully expired, and the mutual release
becomes fully and finally enforceable. The parties hereto acknowledge that the Termination Compensation to be provided under
this Section 5(c) is in consideration for CONSULTANT’s release.

    	 	2	 

    	 	 	 

    

 

(d) 
Termination for CONSULTANT’s Permanent
Disability. To the extent permissible under applicable law, in the event the CONSULTANT becomes permanently disabled during
the term of this Agreement with the Company, the Company may terminate the CONSULTANT’s under this Agreement by giving thirty
(30) days’ notice to the CONSULTANT of its intent to terminate his engagement, and unless the CONSULTANT resumes performance
of the duties set forth in Paragraph 3 within five (5) days of the date of the notice and continues performance for the remainder
of the notice period, the CONSULTANT shall terminate at the end of the thirty (30)-day period. The CONSULTANT will not be entitled
to and shall not receive any compensation or benefits of any type following the effective date of termination except as available
under any disability policy covering the CONSULTANT as of his termination date. “Permanently disabled” for the purposes
of this Agreement means the CONSULTANT’s inability, due to physical or mental ill health, to perform the essential functions
of his job, with or without a reasonable accommodation, for the period of six (6) months during any one engagement year.

 

(e) 
Termination Due to CONSULTANT’s Death.
The CONSULTANT’s engagement under this Agreement will terminate immediately upon his death and the Company shall not have
any further liability or obligations to the CONSULTANT’s estate, his executors, heirs, assigns or any other person claiming
under or through his estate, except that CONSULTANT’s estate shall receive any accrued but unpaid compensation or bonuses
and any life insurance benefits to be paid pursuant to the CONSULTANT’s beneficiary designation and shall have the right
to exercise the options granted under this Agreement. 

 

(g)
Expiration of the Agreement and its Effect on
Termination Compensation. If the Agreement expires at the end of the Initial Term or any renewal term after proper
advance notice by either party of its/his intent not to renew, the Agreement shall expire, and the CONSULTANT shall not be entitled
to any Termination Compensation of any kind, except as required by law.

 

		7.	Company
                                         Property.

 

All
correspondence, records, documents, software, promotional materials, and other Company property, including all copies, which come
into the CONSULTANT’s possession by, through or in the course his engagement, regardless of the source and whether created
by the CONSULTANT, are the sole and exclusive property of the Company, and immediately upon the termination of the CONSULTANT’s
engagement, with or without cause, or at any time on the Company’s request, the CONSULTANT shall return to the Company all
such property of the Company, without retaining any copies, summaries or excerpts of any kind or in any format whatsoever.

 

		8.	Non-Competition/Non-Solicitation:

 

(a)    The
CONSULTANT agrees and acknowledges that, in connection with his engagement with the Company, he will be provided with access
to and become familiar with confidential and proprietary information and trade secrets belonging to the Company. In
consideration of his engagement with the Company pursuant to this Agreement and for other good and valuable consideration,
the receipt of which is hereby acknowledged, the CONSULTANT agrees that, while he is engaged by the Company and for a one (1)
year period after the termination of his engagement, with or without cause, he shall not, either on his own behalf or on
behalf of any third party, except on behalf of the Company, directly or indirectly, engage in any of the following
activities.

    	 	3	 

    	 	 	 

    

 

(1)  
Other than through his ownership of stock of
the Company, directly or indirectly, own, manage, operate, join, control, or participate in the ownership, management, operation
control, or be connected as proprietor, partners, stockholder, officer, director, principal, agent, representative, joint venturer,
investor, lender, consultant or otherwise with, or use or permit his name to be used in connection with, any business or enterprise
engaged directly or indirectly in competition with the business conducted by the Company, at any time during such period, The
foregoing restriction shall not be construed to prohibit the CONSULTANT’s ownership of not more than one percent (1%) of
any class of securities of any corporation that is engaged in any of the foregoing businesses having a class of securities registered
pursuant to the Securities Exchange Act of 1934, as amended; or

 

(2)  
Attempt in any manner to solicit from any client
or customer of the Company at the time of the CONSULTANT’s termination, business of the type performed by the Company or
to persuade any client of the Company to cease to do business or to reduce the amount of business which any such client has customarily
done or actively contemplates doing with the Company; or

 

(3) 
Recruit, solicit or induce, or attempt to induce,
any employee or employees of the Company or its affiliates to terminate their employment with, or otherwise cease their relationship
with the Company or its affiliates.

 

(b)  
The parties acknowledge and agree that the restrictions
placed upon the CONSULTANT herein are reasonable and necessary to protect the Company’s legitimate interests. The CONSULTANT
further acknowledges that, based upon his education, experience, and training, this non-compete provision will not prevent him
from earning a livelihood and supporting himself and his family during the relevant time period.

 

(c)  
If any restriction set forth in this Section
7 is found by any court of competent jurisdiction to be unenforceable as overbroad, it shall be reformed and interpreted to extend
over the maximum period of time, range of activities or geographic areas as to which
it may be enforceable.

 

		(d)	The
                                         provisions of this Section 7 shall survive termination or expiration of this Agreement.

 

		9.	Protection
                                         of Confidential Information.

 

The
CONSULTANT agrees that all information, whether or not in writing, relating to the business, technical or financial affairs of
the Company and that is generally understood in the industry as being confidential and/or proprietary information is the sole
and exclusive property of the Company. The CONSULTANT agrees to hold in a fiduciary capacity for the sole benefit of the Company
all secret, confidential or proprietary information, knowledge, data, or trade secret (“Confidential Information”)
relating to the Company or any of its affiliates or their respective clients, which Confidential Information shall have been obtained
during his engagement with the Company. This Confidential Information shall include, but not be limited to, information regarding
the Company’s trade secrets, inventions, patent, trademark and copyright applications, cost and pricing data, customer and
supplier lists, specifications, financial data, schematics and prototypes. The CONSULTANT agrees that he will not, at any time,
either during the Term of this Agreement or after its termination, disclose to anyone any Confidential Information, or utilize
such Confidential Information for his own benefit, or for the benefit of third parties without written approval by an officer
of the Company. The CONSULTANT further agrees that all memoranda, notes, records, data, schematics, sketches, computer programs,
prototypes or written,

    	 	4	 

    	 	 	 

    

photographic,
magnetic or other documents or tangible objects compiled by him or made available to him during the Term of his engagement concerning
the business of the Company and/or its clients, including any copies of such materials, shall be the sole and exclusive property
of the Company and shall be delivered to the Company on the termination of his engagement, or at any other time upon the Company’s
request.

 

		10.	Injunctive
                                         Relief.

 

The
CONSULTANT understands that, in the event he breaches this Agreement, the Company may suffer irreparable harm and will, therefore,
be entitled to injunctive relief without the posting of a bond or other guarantee, to enforce this Agreement. This provision is
not a waiver of any other rights that the Company may have under this Agreement, including the right to recover attorneys’
fees and costs to cover the expenses it incurs in seeking to enforce this Agreement, as well as to any other remedies available
to it, including money damages.

 

		11.	Binding
                                         Agreement.

 

This
Agreement shall be binding upon and inure to the benefit of the parties hereto, their heirs, personal representatives, successors
and assigns. In the event the Company is acquired, is a non-surviving party in a merger, or transfers substantially all of its
assets, this Agreement shall not be terminated and the transferee or surviving company shall be bound by the provisions of this
Agreement. The parties understand that the obligations of the CONSULTANT are personal and may not be assigned by him. This
Agreement can only be modified if mutually agreeable and in writing executed by both parties.

 

12.
 Nonassignability.

 

This
Agreement and all rights, liabilities and obligations hereunder will be binding upon and inure to the benefit of each party’s
successors, but neither party will assign, transfer or subcontract this Agreement or any of its obligations hereunder without
the other party’s express, prior written consent.

 

		13.	Severability.

In
the event that any term or provision of this Agreement is held invalid, void or unenforceable, then the remainder of this Agreement
will not be affected, impaired or invalidated, and each such term and provision of this Agreement will be valid and enforceable
to the fullest extent permitted by law.

 

		14.	Governing
                                         Law.

Regardless
of the place of execution or performance, this Agreement and any related indemnification and confidentiality agreements between
the parties will be deemed made in California. All actions arising hereunder or in connection herewith will fall under the exclusive
jurisdiction and venue of the American Arbitration Association located in Los Angeles, CA and each of the parties hereto hereby
agrees to the personal jurisdiction and venue of said arbitrator. The parties hereto agree to service of process by certified
mail or receipted courier. Any right to trial by jury with respect to any claim or proceeding related to or arising out of this
engagement, or any transaction or conduct in connection herewith, is waived.

 

15..
Advisory Services. Consultant is not a registered broker-dealer, attorney, accountant, negotiator, or
financial advisor to the Company. Consultant will not make any recommendations about the Services and the Company will
seek its own professional advice with respect to the Services. All payments made hereunder are nonrefundable.

    	 	5	 

    	 	 	 

    

16.    
Notices.
All notices, requests and demands hereunder will be in writing and will be deemed to have been duly given (a) upon personal delivery,
(b) five (5) days after being mailed by registered or certified mail, return receipt requested, (c) one (1) business day after
being sent by email, or (c) one (1) business day after being sent by nationally recognized overnight courier.

 

17.    
Independent Contractor.
The parties expressly intend and agree that Consultant is acting as an independent contractor of Company and is not providing
the services under the direction or control of the Company. Nothing contained in this Agreement shall be deemed to create a partnership,
joint venture or agency or employer/employee relationship between the parties, nor does it grant either party any authority to
assume or create any obligation on behalf of or in the name of the other. The Consultant has no authority to obligate or bind
the Company by contract or otherwise. The Consultant will not be eligible for any employee benefits, and the Company will not
make deductions from the Consultant’s fees for taxes (except as otherwise required by applicable law or regulation). Any
taxes imposed on the Consultant due to the services performed hereunder will be the sole responsibility of the Consultant. Consultant
shall have the sole responsibility for ensuring that it complies with all laws in the performance of the services, and all tax
payment and reporting obligations of the United States and the country, state and city in which Consultant resides.

 

 

[Signature
Page Follows]

    	 	6	 

    	 	 	 

    

IN
WITNESS WHEREOF, the undersigned have
executed this Agreement as of the date first above written.

 

 

 

Richard
L. Chang Holdings, LLC

 

By:
/s/ Richard L. Chang

Name:
Prof. Richard L. Chang

 

 

MEGA
BRIDGE. (to be known as HYPGEN INC.)

 

By:
/s/ McCoy Moretz

Name:
McCoy Moretz, MD

Title:
CEO

    	 	7SUPPORT
AND COLLABORATION AGREEMENT

 

This
Support and Collaboration Agreement (the “Agreement”) is effective
as of July 11, 2017 ("Effective Date") by and between Rich Pharmaceuticals, Inc., a Nevada corporation (“Rich”),
and Mega Bridge, Inc., a Nevada corporation, to be renamed “Hypgen” (“Hypgen”).

 

WHEREAS,
Hypgen has been assigned United States Utility Patent Application No. 62/420,177 filed on November 10, 2016 titled “COMPOSITIONS
AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF PARKINSON’S DISEASE” and all relatedintellectual property,
inventions and trade secrets, data, and clinical study results (the “Parkinson’s Indication”),
and Hypgen desires to seek FDA approval for the use of the Parkinson’s Indication;

 

WHEREAS,
Rich has expended substantial time and resources in developing data and an FDA submission package for RP-323 (TMA Treatment for
AML) which has significant value to Hypgen in the FDA approval process for the Parkinson’s Indication;

 

WHEREAS,
the parties desire to collaborate for Hypgen’s access to and use of certain Rich data and raw material to allow for the
FDA approval process for the Parkinson’s Indication to be expedited and substantially more cost-efficient;

 

NOW,
THEREFORE, in consideration of the above recitals and for other good and valuable consideration, the receipt and adequacy of which
are hereby acknowledged, Rich and Hypgen hereby agree as follows:

 

		1.	DEFINITIONS.

 

1.1.           
 Agreement shall mean this agreement between Rich and
Hypgen, including all amendments and modifications hereto.

 

1.2             
Confidential Information shall mean all information which
is (i) in tangible form and either marked “Confidential”, “Proprietary”, or some other manner to indicate
its confidential nature, (ii) oral information disclosed pursuant to this Agreement designated at its disclosure as confidential
and within thirty (30) days thereafter is confirmed in writing; or (iii) tangible or oral information which is confidential by
its nature and not known by the other party at the time of its disclosure.

 

1.3             
Data and Raw Materials shall mean all data generated by Rich as follows: (i) full access to IRB #124642 submission package
including but not limited to the Investigator Brochure, all protocols, any and all attachments, data, application, existing publications,
analytical assays and all communications between Rich and the USFDA; (ii) access to sources such as clinical sites, Principal
investigators/doctors, medical and scientific advisors, access to Rich’s CRO’s and their knowledge of RP-323; and
(iii) raw material need for one minimum batch run of RP-323; enough clinical drug to run a complete Phase II. 

 

    	 	1	 

    	 	 	 

    

		2.	ACCESS
                                         TO DATA AND RAW MATERIALS; ADVISORY

 

2.1             
Access to Data and Raw Materials. Rich shall grant to Hypgen personnel full access to and use of the Data and the Raw Materials
to permit Hypgen the benefit of the Data and Raw Materials for the FDA approval process for the Parkinson’s Indication.

 

2.2             
Advisory Support. Rich shall cause
its employees and consultants to provide commercially reasonable advisory support to Hypgen to utilize the Data and Raw Materials.

 

		3.	COMPENSATION.

 

3.1             
Cash Compensation. Upon execution of this Agreement,
Hypgen shall pay to Rich the amount of $100,000.

 

3.2             
Equity Compensation. Within ten (10) days after execution of this Agreement, Hypgen shall issue to Rich the amount of 15,000,000
shares of Hypgen Common Stock. Rich shall dividend a minimum of 5,000,000 shares of the Hypgen Common Stock to its shareholders
at such time as Rich completes the necessary and required corporate and regulatory
requirements in connection with the dividend.

 

		4.	CONFIDENTIALITY.

 

Each
party hereby acknowledges that the Confidential Information of the other party is a valuable asset of such other party. Each party
agrees to hold all such Confidential Information of the other party in confidence, and agrees not to disclose such Confidential
Information, except as expressly permitted by the terms of this Agreement, to anyone other than such party's employees with a
bona fide need to know, which employees shall be governed by a parallel confidentiality obligation of equal or greater force.
Additionally, each party agrees to use at least that degree of care, which it uses to protect its own information of a similar
proprietary nature, but in no event less than reasonable protection. Excluded from such Confidential Information is information
that the receiving party can prove by clear and convincing written evidence that it had in its possession without Confidential
Information prior to disclosure, which is known or becomes known to the general public without breach of this Agreement or which
is received rightfully by the receiving party and without confidentiality limitations from a third party or which is disclosed
publicly by the disclosing party without substantially similar confidentiality restrictions. Each party acknowledges that the
unauthorized disclosure of the Confidential Information of the other party could cause irreparable harm and significant injury
to the other party, which may be difficult to ascertain. Accordingly, each party agrees that the other party shall have the right
to obtain an immediate injunction enjoining any such unauthorized disclosure.

 

		5.	TITLE
                                         AND IP OWNERSHIP.

 

Rich
shall retain all right, title and interest in and to the intellectual property related to the Data and RP-323. Hypgen shall retain
all right, title and interest in and to the intellectual property related to the Parkinson’s Indication and all new data
and materials derived and developed from access to the Data.

    	 	2	 

    	 	 	 

    

		6.	COMPLIANCE
                                         WITH GOVERNMENTAL OBLIGATIONS.

 

Each
party shall comply upon reasonable notice from the other party with all governmental requests relating to the subject of this
Agreement directed to either party and provide all information and assistance reasonably necessary to comply with the governmental
request.

 

		7.	INDEMNITY.

 

7.1.           
Indemnity by Rich. Rich agrees to
indemnify and hold Hypgen harmless from any and all claims, suits, liabilities, judgments, penalties, losses, costs, damages,
and expenses resulting therefrom, including reasonable attorney’s fees, based upon or arising out of (i) a claim that all
or a portion of the Data infringes any intellectual property owned by any third parties;
or (ii) the breach of this Agreement by Rich.

 

7.1.1.     
Notice. In the event of any action subject to Paragraph 7.1, Hypgen agrees to (i) notify Rich promptly of any claim covered
by Paragraph 7.1; (ii) permit Rich to assume direction and control of the defense of such claim (including the right to settle
such claim at the sole discretion of Rich); and (iii) cooperate as reasonably requested in the defense of such claim at Hypgen's
expense.

 

7.1.2
Remedies. In consideration for the indemnity provided in Section 7.1(i), the parties agree that Rich may: (i) obtain a license
or make other arrangement that permits Hypgen to continue to use the Data; or (ii)
provide Hypgen with modifications to or substitutions for the Data that will not materially affect the functionality of the Data.

 

7.2.           
Indemnity by Hypgen. Hypgen agrees to indemnify and hold Rich harmless from any and all actions, claims, suits, liabilities,
judgments, penalties, losses, costs, damages, and expenses resulting therefrom, including reasonable attorney’s fees, based
upon or arising out of the breach of this Agreement by Hypgen.

 

7.2.1
Notice. In the event of any action subject to Paragraph 7.2, Rich agrees to (i) notify Hypgen promptly of any claim covered
by Paragraph 7.2; (ii) permit Hypgen to assume direction and control of the defense of such claim (including the right to settle
such claim at the sole discretion of Hypgen) and (iii) cooperate as reasonably requested in the defense of such claim at Rich’s
expense.

 

		8.	LIMITATION
                                         OF LIABILITY.

 

EXCEPT
WITH RESPECT TO THE INDEMNITY OBLIGATIONS SET FORTH IN
SECTION 7, NEITHER PARTY SHALL HAVE ANY LIABILITY FOR CONSEQUENTIAL,
INCIDENTAL, SPECIAL, PUNITIVE OR INDIRECT DAMAGES (INCLUDING LOSS OF PROFIT AND BUSINESS OPPORTUNITIES) REGARDLESS
OF WHETHER SUCH PARTY HAS BEEN ADVISED
OF, OR IS AWARE THAT, SUCH DAMAGES HAVE BEEN, OR MAY BE INCURRED. TO THE EXTENT PERMITTED BY APPLICABLE LAW, EACH PARTY
WAIVES ALL CLAIMS BASED ON A THEORY OF QUANTUM MERUIT.

 

		9.	TERM,
                                         RENEWAL, AND TERMINATION.

 

9.1             
Term. Upon execution of this Agreement, the term of
this Agreement (“Term”) shall be for three (3) years from the Effective Date, and the Term shall automatically
renew for successive periods of one (1) year unless one party provides written notice to the other party of its intent not to
renew the Term and such notice is delivered at least 90 days before the expiration of the then current Term.

    	 	3	 

    	 	 	 

    

9.2             
Termination for Material Breach. Each party shall have the right to terminate this Agreement upon breach of a material provision
thereof by the other party. Such termination shall become effective upon (i) the non-breaching party sending written notice to
the breaching party specifying the breach, and (ii) the failure of the breaching party to demonstrate, to the commercially reasonable
satisfaction of the non-breaching party, that the breaching party has cured such breach within ten (10) calendar days of the receipt
of notice of a financial breach, and sixty (60) calendar days of the receipt of notice of all other such breaches.

 

9.3             
Other Terminations. This Agreement may be terminated
by Rich with thirty (30) calendar days’ written notice to Hypgen without right to cure, upon the occurrence of any of the
following events: if Hypgen files a petition in bankruptcy or the equivalent thereof, or is the subject of an involuntary petition
in bankruptcy that is not dismissed within sixty (60) calendar days after the filing date thereof, or is or becomes insolvent,
or admits of a general inability to pay its debts as they become due. This Agreement may be terminated by Hypgen with thirty (30)
calendar days’ written notice to Rich without right to cure, upon the occurrence of any of the following events: if Rich
files a petition in bankruptcy or the equivalent thereof, or is the subject of an involuntary petition in bankruptcy that is not
dismissed within sixty (60) calendar days after the filing date thereof, or is or becomes insolvent, or admits of a general inability
to pay its debts as they become due. Any expiration or termination of this Agreement shall not affect the perpetual licenses of
the Data granted to Hypgen under this Agreement.

 

9.4             
Survival. The following shall survive expiration or termination of this Agreement: Sections 4, 5, 7, 8, 9.4 and 10.

 

		10.	MISCELLANEOUS
                                         PROVISIONS.

 

10.1         
Assignment.
This Agreement may
not be assigned by either party without the prior written consent of the other party.

 

10.2          
Relationship. Nothing in this Agreement shall be construed to create a principal-agent relationship, partnership or joint
venture between the parties, or give rise to any fiduciary duty from one party to the other party. Neither party may make any
commitments or incur any liabilities on behalf of the other party. Neither party is a legal representative or legal agent of the
other. Neither party is legally a partner of the other, and neither party is an employee or franchisee of the other, nor does
this Agreement create a joint venture between the parties.

 

10.3         
Severability. If any provision of this Agreement is held by a court of competent
jurisdiction to be unenforceable or contrary to law, the remaining provisions of this Agreement shall remain in full force and
effect.

 

10.4         
No Waiver. The failure of either party at any time to require performance by the other party of any provision of this Agreement
shall not be construed as acquiescence or waiver of such failure to perform such provision. The failure of either party to take
action upon the breach of any provision of this Agreement shall not be construed as acquiescence or waiver of any such breach.

    	 	4	 

    	 	 	 

    

10.5         
Binding on Successors. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
assigns to the extent assignment is permitted by this Agreement.

 

10.6         
Representation of Counsel; Mutual Negotiation. Each party has been represented by counsel of its choice in negotiating this
Agreement. This Agreement shall therefore be deemed to have been negotiated at arms-length, with the advice and participation
of counsel, and prepared at the joint request, direction, and instruction of the parties, and shall be interpreted in accordance
with its terms without favor to either party.

 

10.7         
Choice of Law. The validity, construction and performance of this Agreement shall be governed by the substantive law of the
State of Nevada, without regard to the conflict of law rules in the jurisdiction where a claim arose. The exclusive venue for
any dispute arising under this Agreement shall be within the competent courts in the State of Nevada.

 

10.8         
No Third Party Beneficiaries. Nothing in this Agreement shall be construed to give rise to or change any obligation on either
party hereto for the benefit of a third party or to confer any rights on any third party.

 

10.9         
Force Majeure. Except with regard to obligations to pay
amounts due hereunder, each party shall be excused from performance in the event and to the extent of any occurrence of force
majeure, including but not limited to strikes, lockouts, and other labor disputes, wars, revolutions, civil strife, riots, disturbances,
acts of enemies, accidents, typhoons, hurricanes, fires, floods, earthquakes, diseases, hazards of transportation, material shortages,
acts of state, and all other causes beyond the control of such party.

 

10.10     
Entire Agreement. The provisions of this Agreement, including any attachments and amendments, constitute the entire agreement
between the parties and supersede any and all prior communications and understandings, oral or written, and prevail over any additional
terms contained in any prior or subsequent quote, purchase order or other communication between the parties relating to the subject
matter hereof. No amendment of this Agreement or its terms shall be effective unless such amendment is in writing, specifically
references this Agreement and is signed by all parties hereto.

 

10.11       
Counterparts. This Agreement may be executed by any of the parties hereto in counterparts and delivered by electronic delivery
via facsimile or by e-mail in PDF, each of which shall be deemed to be an original, but all such counterparts shall together constitute
one and the same Agreement. 

 

    	 	5	 

    	 	 	 

    

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date indicated above.

 

	MEGA
                                         BRIDGE, INC.,

        a
        Nevada corporation
	RICH
                                         PHARMACEUTIALS, INC.,

        a
        Nevada corporation

	 

        By:
        /s/ Dr. McCoy Moretz,

        Dr.
        McCoy Moretz

        Chief
        Executive Officer
	 

        By:
        /s/ Ben Chang,

        Ben
        Chang

        Chief
        Executive Officer

 

    	 	6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}]]